Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Capeox clinical trials

Also listed in trial records as AK112 with SCRT and CapeOX
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 13 trials in our China, UK, Spain, Italy, Belgium, Japan, Switzerland, USA, India, Germany, France, Netherlands, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan and Australia registers that name Capeox as an intervention. Synced 10 Nov 2026
13Current trials
10Recruiting now
9Lead sponsors
24Country registers
At a glance

Capeox is named as an intervention in 13 current clinical trials in our China, UK, Spain, Italy, Belgium, Japan, Switzerland, USA, India, Germany, France, Netherlands, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan and Australia registers. 10 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is GlaxoSmithKline (2). The most-studied condition is Rectal Cancer.

Patient leaflets for Capeox

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting1077%
  • Not yet open215%
  • Active, closed18%

Trials by phase

  • Phase 2862%
  • Phase 3323%
  • Phase 118%
  • Phase 2/318%
01

Clinical trials of Capeox

13 trials
StudyPhaseStatusLead sponsorRegisters
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
NCT05201430 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 3 Recruiting Fudan University China
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200 · Colonic Neoplasms, Neoplasms, Colon
Phase 3 Recruiting GlaxoSmithKline UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
NCT05576480 · ClinicalTrials.gov ↗ · Rectal Cancer, Locally Advanced
Phase 2 Recruiting Ruijin Hospital China
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
NCT06567782 · Neoplasms, Colon
Phase 2 Recruiting GlaxoSmithKline UK, Spain, Italy, Belgium, Switzerland, Japan
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
NCT06709885 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma
Phase 2 Recruiting Daping Hospital and the Research Institute of Surgery of the Third Military Medical University China
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
NCT06718543 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 2 Recruiting fan li China
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
NCT07007182 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Stomach Neoplasms
Phase 2 Recruiting Jinbo Yue China
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
NCT07468630 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma
Phase 2 Recruiting Daping Hospital and the Research Institute of Surgery of the Third Military Medical University China
Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer
NCT07562503 · ClinicalTrials.gov ↗ · ctDNA, Colorectal Cancer, Chemotherapy
Phase 2 Recruiting Fudan University China
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
NCT06621563 · ClinicalTrials.gov ↗ · Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
Phase 1 Recruiting Hansoh BioMedical R&D Company China
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
NCT06443671 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 2/3 Not yet open Peking University Cancer Hospital & Institute China
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
NCT07007728 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
Phase 2 Not yet open Peking University Cancer Hospital & Institute China
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
NCT06246344 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 3 Active, closed Shandong Cancer Hospital and Institute China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Capeox

14 conditions
All 14 conditions
Condition (as registered)Trials
Rectal Cancer5
Neoplasms, Colon2
Colorectal Cancer2
Colon Adenocarcinoma2
Colonic Neoplasms1
ctDNA1
Chemotherapy1
Solid Tumors1
Non-Small Cell Lung Cancer1
Gastric Adenocarcinoma1
Stomach Neoplasms1
Colorectal Neoplasms1
Secondary Malignant Neoplasm of Liver1
Locally Advanced1
05

Related compounds

06

Questions about Capeox trials

How many clinical trials are testing Capeox?

13 current trials in our China, UK, Spain, Italy, Belgium, Japan, Switzerland, USA, India, Germany, France, Netherlands, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan and Australia registers name Capeox (also registered as AK112 with SCRT and CapeOX) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Capeox trials recruiting patients?

Yes. 10 of the 13 trials are recruiting: 9 with sites in China, 2 with sites in UK, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Belgium, 2 with sites in Japan, 1 with sites in Switzerland, 1 with sites in USA, 1 with sites in India, 1 with sites in Germany, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Sweden, 1 with sites in Poland, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in South Korea, 1 with sites in Taiwan and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Capeox clinical trials?

GlaxoSmithKline (2), Fudan University (2), Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2) and Peking University Cancer Hospital & Institute (2), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Capeox works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Capeox works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Capeox (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.